They say these low-cost, high-impact viruses are showing promise in clinical trials – there are around 60 currently under way ...

Backed by a $2 million grant, University of New Mexico Comprehensive Cancer Center professor Eric Bartee's research raises ...

A new cancer therapy utilising a genetically modified herpes simplex virus type 1 (HSV-1) offers hope for late-stage patients ...

Brain cancer, notorious for its aggressiveness and limited treatment options, may finally have a powerful ally.A patient at ...

Experimental therapy uses a modified virus to boost immunity and make anti-tumour treatments more effective, according to ...

Merck & Co’s $394 million acquisition of Viralytics has stoked interest in oncolytic viruses, a class of drugs that have been in the shadow of the checkpoint inhibitors and CAR-T therapies that ...

Delytact (teserpaturev) is a genetically engineered oncolytic herpes simplex virus type 1 (HSV-1) that was approved for marketing in Japan earlier this year, and received pricing approval in ...

Candel Therapeutics has identified a subpopulation of lung cancer patients living longest on its oncolytic virus, leading the biotech to narrow its focus as it heads towards a potentially ...

Instead, the focus of its current funding and research teams will now be VCN-01, an oncolytic adenovirus that is in multiple early or midstage trials for several conditions, including metastatic ...